Skip to main content
SpringerLink
Log in

The Pulmonary Vasculature in Chronic Obstructive Lung Disease

  • Chapter
  • First Online:
Endothelial Signaling in Development and Disease

Abstract

Chronic obstructive pulmonary disease (COPD) is a leading cause of death worldwide and is still incurable. COPD encompasses chronic bronchitis and emphysema. It has recently been shown that vascular wall remodeling and pulmonary hypertension (PH) can occur in smokers who exhibit no deterioration in lung function and gas exchange, suggesting a causal role of vascular alterations for the development of emphysema. Recent advances investigating cellular and molecular mechanisms demonstrate that abnormalities in the vasculature, such as endothelial dysfunction, inflammation, altered cellular apoptosis/proliferation balance, and elevated oxidative and nitrosative stress can be a driving force for the development of PH, cor pulmonale, and most probably pulmonary emphysema. The identification of key players affecting the vasculature could potentially lead to treatments of not only PH but also COPD.

Thus, elucidation of the role of vascular alterations and their mechanisms in COPD may offer new insights into the pathophysiology of this disease, including the development of new therapeutic concepts.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J. 2003;21(2):347–60.

    Article  CAS  PubMed  Google Scholar 

  2. Sertogullarindan B, Gumrukcuoglu HA, Sezgi C, Akil MA. Frequency of pulmonary hypertension in patients with COPD due to biomass smoke and tobacco smoke. Int J Med Sci. 2012;9(6):406–12.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Black PN, Ching PS, Beaumont B, Ranasinghe S, Taylor G, Merrilees MJ. Changes in elastic fibres in the small airways and alveoli in COPD. Eur Respir J. 2008;31(5):998–1004.

    Article  CAS  PubMed  Google Scholar 

  4. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med. 2000;343(4):269–80.

    Article  CAS  PubMed  Google Scholar 

  5. Sharafkhaneh A, Hanania NA, Kim V. Pathogenesis of emphysema: from the bench to the bedside. Proc Am Thorac Soc. 2008;5(4):475–7.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Churg A, Cosio M, Wright JL. Mechanisms of cigarette smoke-induced COPD: insights from animal models. Am J Physiol Lung Cell Mol Physiol. 2008;294(4):L612–31.

    Article  CAS  PubMed  Google Scholar 

  7. Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med. 1997;156(2 Pt 1):341–57.

    Article  CAS  PubMed  Google Scholar 

  8. Barbera JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J. 2003;21(5):892–905.

    Article  CAS  PubMed  Google Scholar 

  9. Peinado VI, Pizarro S, Barbera JA. Pulmonary vascular involvement in COPD. Chest. 2008;134(4):808–14.

    Article  CAS  PubMed  Google Scholar 

  10. Wright JL, Levy RD, Churg A. Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment. Thorax. 2005;60(7):605–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Naeije R. Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2(1):20–2.

    Article  PubMed  Google Scholar 

  12. Scharf SM, Iqbal M, Keller C, Criner G, Lee S, Fessler HE. Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med. 2002;166(3):314–22.

    Article  PubMed  Google Scholar 

  13. Cuttica MJ, Kalhan R, Shlobin OA, Ahmad S, Gladwin M, Machado RF, Barnett SD, Nathan SD. Categorization and impact of pulmonary hypertension in patients with advanced COPD. Respir Med. 2010;104(12):1877–82.

    Article  PubMed  Google Scholar 

  14. Oswald-Mammosser M, Weitzenblum E, Quoix E, Moser G, Chaouat A, Charpentier C, Kessler R. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest. 1995;107(5):1193–8.

    Article  CAS  PubMed  Google Scholar 

  15. Minai OA, Chaouat A, Adnot S. Pulmonary hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global perspective. Chest. 2010;137(6 Suppl):39S-51S.

    Google Scholar 

  16. Blanco I, Gimeno E, Munoz PA, Pizarro S, Gistau C, Rodriguez-Roisin R, Roca J, Barbera JA. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med. 2010;181(3):270–8.

    Article  CAS  PubMed  Google Scholar 

  17. Pynnaert C, Lamotte M, Naeije R. Aerobic exercise capacity in COPD patients with and without pulmonary hypertension. Respir Med. 2010;104(1):121–6.

    Article  PubMed  Google Scholar 

  18. Orr R, Smith LJ, Cuttica MJ. Pulmonary hypertension in advanced chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2012;18(2):138–43.

    Article  PubMed  Google Scholar 

  19. Ferrer E, Peinado VI, Diez M, Carrasco JL, Musri MM, Martinez A, Rodriguez-Roisin R, Barbera JA. Effects of cigarette smoke on endothelial function of pulmonary arteries in the guinea pig. Respir Res. 2009;10:76.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Seimetz M, Parajuli N, Pichl A, Veit F, Kwapiszewska G, Weisel FC, Milger K, Egemnazarov B, Turowska A, Fuchs B, et al. Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. Cell. 2011;147(2):293–305.

    Article  CAS  PubMed  Google Scholar 

  21. Wright JL, Churg A. Cigarette smoke causes physiologic and morphologic changes of emphysema in the guinea pig. Am Rev Respir Dis. 1990;142(6 Pt 1):1422–8.

    Article  CAS  PubMed  Google Scholar 

  22. Wright JL, Churg A. Effect of long-term cigarette smoke exposure on pulmonary vascular structure and function in the guinea pig. Exp Lung Res. 1991;17(6):997–1009.

    Article  CAS  PubMed  Google Scholar 

  23. Santos S, Peinado VI, Ramirez J, Melgosa T, Roca J, Rodriguez-Roisin R, Barbera JA. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J. 2002;19(4):632–8.

    Article  CAS  PubMed  Google Scholar 

  24. Schrijen F, Uffholtz H, Polu JM, Poincelot F. Pulmonary and systemic hemodynamic evolution in chronic bronchitis. Am Rev Respir Dis. 1978;117(1):25–31.

    CAS  PubMed  Google Scholar 

  25. Weitzenblum E, Loiseau A, Hirth C, Mirhom R, Rasaholinjanahary J. Course of pulmonary hemodynamics in patients with chronic obstructive pulmonary disease. Chest. 1979;75(6):656–62.

    Article  CAS  PubMed  Google Scholar 

  26. Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Hirth C, Roegel E. Long-term course of pulmonary arterial pressure in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1984;130(6):993–8.

    CAS  PubMed  Google Scholar 

  27. Kessler R, Faller M, Weitzenblum E, Chaouat A, Aykut A, Ducolone A, Ehrhart M, Oswald-Mammosser M. “Natural history” of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med. 2001;164(2):219–24.

    Article  CAS  PubMed  Google Scholar 

  28. MacNee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part One. Am J Respir Crit Care Med. 1994;150(3):833–52.

    Article  CAS  PubMed  Google Scholar 

  29. Richens JM, Howard P. Oedema in cor pulmonale. Clin Sci (Lond). 1982;62(3):255–9.

    Article  CAS  Google Scholar 

  30. Farber MO, Weinberger MH, Robertson GL, Fineberg NS, Manfredi F. Hormonal abnormalities affecting sodium and water balance in acute respiratory failure due to chronic obstructive lung disease. Chest. 1984;85(1):49–54.

    Article  CAS  PubMed  Google Scholar 

  31. MacNee W, Wathen CG, Flenley DC, Muir AD. The effects of controlled oxygen therapy on ventricular function in patients with stable and decompensated cor pulmonale. Am Rev Respir Dis. 1988;137(6):1289–95.

    Article  CAS  PubMed  Google Scholar 

  32. Weitzenblum E, Apprill M, Oswald M, Chaouat A, Imbs JL. Pulmonary hemodynamics in patients with chronic obstructive pulmonary disease before and during an episode of peripheral edema. Chest. 1994;105(5):1377–82.

    Article  CAS  PubMed  Google Scholar 

  33. Bishop JM, Cross KW. Physiological variables and mortality in patients with various categories of chronic respiratory disease. Bull Eur Physiopathol Respir. 1984;20(6):495–500.

    CAS  PubMed  Google Scholar 

  34. Chaouat A, Bugnet AS, Kadaoui N, Schott R, Enache I, Ducolone A, Ehrhart M, Kessler R, Weitzenblum E. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172(2):189–94.

    Article  PubMed  Google Scholar 

  35. Barbera JA, Riverola A, Roca J, Ramirez J, Wagner PD, Ros D, Wiggs BR, Rodriguez-Roisin R. Pulmonary vascular abnormalities and ventilation-perfusion relationships in mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1994;149(2 Pt 1):423–9.

    Article  CAS  PubMed  Google Scholar 

  36. Magee F, Wright JL, Wiggs BR, Pare PD, Hogg JC. Pulmonary vascular structure and function in chronic obstructive pulmonary disease. Thorax. 1988;43(3):183–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Peinado VI, Barbera JA, Ramirez J, Gomez FP, Roca J, Jover L, Gimferrer JM, Rodriguez-Roisin R. Endothelial dysfunction in pulmonary arteries of patients with mild COPD. Am J Physiol. 1998;274(6 Pt 1):L908–13.

    CAS  PubMed  Google Scholar 

  38. Eddahibi S, Chaouat A, Morrell N, Fadel E, Fuhrman C, Bugnet AS, Dartevelle P, Housset B, Hamon M, Weitzenblum E, et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation. 2003;108(15):1839–44.

    Article  CAS  PubMed  Google Scholar 

  39. Owens GK. Regulation of differentiation of vascular smooth muscle cells. Physiol Rev. 1995;75(3):487–517.

    CAS  PubMed  Google Scholar 

  40. van der Loop FT, Gabbiani G, Kohnen G, Ramaekers FC, van Eys GJ. Differentiation of smooth muscle cells in human blood vessels as defined by smoothelin, a novel marker for the contractile phenotype. Arterioscler Thromb Vasc Biol. 1997;17(4):665–71.

    Article  PubMed  Google Scholar 

  41. Rabinovitch M. Elastase and the pathobiology of unexplained pulmonary hypertension. Chest. 1998;114(3 Suppl):213S-24S.

    Google Scholar 

  42. Barbera JA. Mechanisms of development of chronic obstructive pulmonary disease-associated pulmonary hypertension. Pulm Circ. 2013;3(1):160–4.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  43. Naeije R, Barbera JA. Pulmonary hypertension associated with COPD. Crit Care. 2001;5(6):286–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  44. Wilkinson M, Langhorne CA, Heath D, Barer GR, Howard P. A pathophysiological study of 10 cases of hypoxic cor pulmonale. Q J Med. 1988;66(249):65–85.

    CAS  PubMed  Google Scholar 

  45. Lejeune P, Mols P, Naeije R, Hallemans R, Melot C. Acute hemodynamic effects of controlled oxygen therapy in decompensated chronic obstructive pulmonary disease. Crit Care Med. 1984;12(12):1032–5.

    Article  CAS  PubMed  Google Scholar 

  46. Timms RM, Khaja FU, Williams GW. Hemodynamic response to oxygen therapy in chronic obstructive pulmonary disease. Ann Intern Med. 1985;102(1):29–36.

    Article  CAS  PubMed  Google Scholar 

  47. Ricciardolo FL, Sterk PJ, Gaston B, Folkerts G. Nitric oxide in health and disease of the respiratory system. Physiol Rev. 2004;84(3):731–65.

    Article  CAS  PubMed  Google Scholar 

  48. Tsoumakidou M, Tzanakis N, Chrysofakis G, Siafakas NM. Nitrosative stress, heme oxygenase-1 expression and airway inflammation during severe exacerbations of COPD. Chest. 2005;127(6):1911–8.

    Article  CAS  PubMed  Google Scholar 

  49. Voelkel NF, Mizuno S, Bogaard HJ. The role of hypoxia in pulmonary vascular diseases: a perspective. Am J Physiol Lung Cell Mol Physiol. 2013;304(7):L457–65.

    Article  CAS  PubMed  Google Scholar 

  50. Stockley RA, Mannino D, Barnes PJ. Burden and pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2009;6(6):524–6.

    Article  CAS  PubMed  Google Scholar 

  51. Peinado VI, Barbera JA, Abate P, Ramirez J, Roca J, Santos S, Rodriguez-Roisin R. Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;159(5 Pt 1):1605–11.

    Article  CAS  PubMed  Google Scholar 

  52. Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Pelletier A. Long-term oxygen therapy can reverse the progression of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1985;131(4):493–8.

    CAS  PubMed  Google Scholar 

  53. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J. 2008;32(5):1371–85.

    Article  CAS  PubMed  Google Scholar 

  54. Fishman AP. Hypoxia on the pulmonary circulation. How and where it acts. Circ Res. 1976;38(4):221–31.

    Article  CAS  PubMed  Google Scholar 

  55. Fishman AP. State of the art: chronic cor pulmonale. Am Rev Respir Dis. 1976;114(4):775–94.

    CAS  PubMed  Google Scholar 

  56. Weitzenblum E, Chaouat A. Cor pulmonale. Chron Respir Dis. 2009;6(3):177–85.

    Article  CAS  PubMed  Google Scholar 

  57. Chao J, Viets Z, Donham P, Wood JG, Gonzalez NC. Dexamethasone blocks the systemic inflammation of alveolar hypoxia at several sites in the inflammatory cascade. Am J Physiol Heart Circ Physiol. 2012;303(2):H168–77.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  58. Chao J, Wood JG, Blanco VG, Gonzalez NC. The systemic inflammation of alveolar hypoxia is initiated by alveolar macrophage-borne mediator(s). Am J Respir Cell Mol Biol. 2009;41(5):573–82.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  59. Prabhakar NR, Kumar GK, Peng YJ. Sympatho-adrenal activation by chronic intermittent hypoxia. J Appl Physiol. 2012;113(8):1304–10.

    Article  PubMed Central  PubMed  Google Scholar 

  60. Wang GL, Semenza GL. Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Chem. 1993;268(29):21513–8.

    CAS  PubMed  Google Scholar 

  61. Archiniegas E, Neves CY, Candelle D, Cardier JE. Thrombin and its protease-activated receptor-1 (PAR1) participate in the endothelial-mesenchymal transdifferentiation process. DNA Cell Biol. 2004;23(12):815–25.

    Article  PubMed  Google Scholar 

  62. Frohlich S, Boylan J, McLoughlin P. Hypoxia-induced inflammation in the lung: a potential therapeutic target in acute lung injury? Am J Respir Cell Mol Biol. 2013;48(3):271–9.

    Article  CAS  PubMed  Google Scholar 

  63. Nicolls MR, Voelkel NF. Hypoxia and the lung: beyond hypoxic vasoconstriction. Antioxid Redox Signal. 2007;9(6):741–3.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  64. Rius J, Guma M, Schachtrup C, Akassoglou K, Zinkernagel AS, Nizet V, Johnson RS, Haddad GG, Karin M. NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature. 2008;453(7196):807–11.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  65. Taylor CT. Interdependent roles for hypoxia inducible factor and nuclear factor-kappaB in hypoxic inflammation. J Physiol. 2008;586(Pt 17):4055–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  66. Yamaji-Kegan K, Su Q, Angelini DJ, Champion HC, Johns RA. Hypoxia-induced mitogenic factor has proangiogenic and proinflammatory effects in the lung via VEGF and VEGF receptor-2. Am J Physiol Lung Cell Mol Physiol. 2006;291(6):L1159–68.

    Article  CAS  PubMed  Google Scholar 

  67. Angelini DJ, Su Q, Kolosova IA, Fan C, Skinner JT, Yamaji-Kegan K, Collector M, Sharkis SJ, Johns RA. Hypoxia-induced mitogenic factor (HIMF/FIZZ1/RELM alpha) recruits bone marrow-derived cells to the murine pulmonary vasculature. PLoS One. 2010;5(6):e11251.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  68. Kuhlicke J, Frick JS, Morote-Garcia JC, Rosenberger P, Eltzschig HK. Hypoxia inducible factor (HIF)-1 coordinates induction of Toll-like receptors TLR2 and TLR6 during hypoxia. PLoS One. 2007;2(12):e1364.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  69. van Uden P, Kenneth NS, Rocha S. Regulation of hypoxia-inducible factor-1alpha by NF-kappaB. Biochem J. 2008;412(3):477–84.

    Article  PubMed Central  PubMed  Google Scholar 

  70. van Uden P, Kenneth NS, Webster R, Muller HA, Mudie S, Rocha S. Evolutionary conserved regulation of HIF-1beta by NF-kappaB. PLoS Genet. 2011;7(1):e1001285.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  71. Savale L, Tu L, Rideau D, Izziki M, Maitre B, Adnot S, Eddahibi S. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res. 2009;10:6.

    Article  PubMed Central  PubMed  Google Scholar 

  72. Steiner MK, Syrkina OL, Kolliputi N, Mark EJ, Hales CA, Waxman AB. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res. 2009;104(2):236–44, (28p following 244).

    Google Scholar 

  73. Brock M, Trenkmann M, Gay RE, Michel BA, Gay S, Fischler M, Ulrich S, Speich R, Huber LC. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circ Res. 2009;104(10):1184–91.

    Article  CAS  PubMed  Google Scholar 

  74. Grijelmo C, Rodrigue C, Svrcek M, Bruyneel E, Hendrix A, de Wever O, Gespach C. Proinvasive activity of BMP-7 through SMAD4/src-independent and ERK/Rac/JNK-dependent signaling pathways in colon cancer cells. Cell Signal. 2007;19(8):1722–32.

    Article  CAS  PubMed  Google Scholar 

  75. Tian Q, He XC, Hood L, Li L. Bridging the BMP and Wnt pathways by PI3 kinase/Akt and 14-3-3zeta. Cell Cycle. 2005;4(2):215–6.

    Article  CAS  PubMed  Google Scholar 

  76. Rudarakanchana N, Flanagan JA, Chen H, Upton PD, Machado R, Patel D, Trembath RC, Morrell NW. Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. Hum Mol Genet. 2002;11(13):1517–25.

    Article  CAS  PubMed  Google Scholar 

  77. Nohe A, Hassel S, Ehrlich M, Neubauer F, Sebald W, Henis YI, Knaus P. The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J Biol Chem. 2002;277(7):5330–8.

    Article  CAS  PubMed  Google Scholar 

  78. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest. 2012;122(12):4306–13.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  79. Atkinson C, Stewart S, Upton PD, Machado R, Thomson JR, Trembath RC, Morrell NW. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation. 2002;105(14):1672–8.

    Article  CAS  PubMed  Google Scholar 

  80. Shimoda LA, Fallon M, Pisarcik S, Wang J, Semenza GL. HIF-1 regulates hypoxic induction of NHE1 expression and alkalinization of intracellular pH in pulmonary arterial myocytes. Am J Physiol Lung Cell Mol Physiol. 2006;291(5):L941–9.

    Article  CAS  PubMed  Google Scholar 

  81. Shimoda LA, Manalo DJ, Sham JS, Semenza GL, Sylvester JT. Partial HIF-1alpha deficiency impairs pulmonary arterial myocyte electrophysiological responses to hypoxia. Am J Physiol Lung Cell Mol Physiol. 2001;281(1):L202–8.

    CAS  PubMed  Google Scholar 

  82. Wang J, Weigand L, Lu W, Sylvester JT, Semenza GL, Shimoda LA. Hypoxia inducible factor 1 mediates hypoxia-induced TRPC expression and elevated intracellular Ca2+ in pulmonary arterial smooth muscle cells. Circ Res. 2006;98(12):1528–37.

    Article  CAS  PubMed  Google Scholar 

  83. Whitman EM, Pisarcik S, Luke T, Fallon M, Wang J, Sylvester JT, Semenza GL, Shimoda LA. Endothelin-1 mediates hypoxia-induced inhibition of voltage-gated K+ channel expression in pulmonary arterial myocytes. Am J Physiol Lung Cell Mol Physiol. 2008;294(2):L309–18.

    Article  CAS  PubMed  Google Scholar 

  84. Moudgil R, Michelakis ED, Archer SL. The role of k+ channels in determining pulmonary vascular tone, oxygen sensing, cell proliferation, and apoptosis: implications in hypoxic pulmonary vasoconstriction and pulmonary arterial hypertension. Microcirculation. 2006;13(8):615–32.

    Article  CAS  PubMed  Google Scholar 

  85. Remillard CV, Yuan JX. High altitude pulmonary hypertension: role of K+ and Ca2+ channels. High Alt Med Biol. 2005;6(2):133–46.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  86. Smirnov SV, Robertson TP, Ward JP, Aaronson PI. Chronic hypoxia is associated with reduced delayed rectifier K+ current in rat pulmonary artery muscle cells. Am J Physiol. 1994;266(1 Pt 2):H365–70.

    CAS  PubMed  Google Scholar 

  87. Grimminger F, Weissmann N, Spriestersbach R, Becker E, Rosseau S, Seeger W. Effects of NADPH oxidase inhibitors on hypoxic vasoconstriction in buffer-perfused rabbit lungs. Am J Physiol. 1995;268(5 Pt 1):L747–52.

    CAS  PubMed  Google Scholar 

  88. Michelakis ED, Hampl V, Nsair A, Wu X, Harry G, Haromy A, Gurtu R, Archer SL. Diversity in mitochondrial function explains differences in vascular oxygen sensing. Circ Res. 2002;90(12):1307–15.

    Article  CAS  PubMed  Google Scholar 

  89. Waypa GB, Schumacker PT. Hypoxic pulmonary vasoconstriction: redox events in oxygen sensing. J Appl Physiol. 2005;98(1):404–14.

    Article  CAS  PubMed  Google Scholar 

  90. Weissmann N, Tadic A, Hanze J, Rose F, Winterhalder S, Nollen M, Schermuly RT, Ghofrani HA, Seeger W, Grimminger F. Hypoxic vasoconstriction in intact lungs: a role for NADPH oxidase-derived H(2)O(2)? Am J Physiol Lung Cell Mol Physiol. 2000;279(4):L683–90.

    CAS  PubMed  Google Scholar 

  91. Weissmann N, Zeller S, Schafer RU, Turowski C, Ay M, Quanz K, Ghofrani HA, Schermuly RT, Fink L, Seeger W, et al. Impact of mitochondria and NADPH oxidases on acute and sustained hypoxic pulmonary vasoconstriction. Am J Respir Cell Mol Biol. 2006;34(4):505–13.

    Article  CAS  PubMed  Google Scholar 

  92. Mittal M, Gu XQ, Pak O, Pamenter ME, Haag D, Fuchs DB, Schermuly RT, Ghofrani HA, Brandes RP, Seeger W, et al. Hypoxia induces Kv channel current inhibition by increased NADPH oxidase-derived reactive oxygen species. Free Radic Biol Med. 2012;52(6):1033–42.

    Article  CAS  PubMed  Google Scholar 

  93. Landsberg JW, Yuan JX. Calcium and TRP channels in pulmonary vascular smooth muscle cell proliferation. News Physiol Sci. 2004;19:44–50.

    CAS  PubMed  Google Scholar 

  94. Reeve HL, Michelakis E, Nelson DP, Weir EK, Archer SL. Alterations in a redox oxygen sensing mechanism in chronic hypoxia. J Appl Physiol. 2001;90(6):2249–56.

    CAS  PubMed  Google Scholar 

  95. Fuchs B, Sommer N, Dietrich A, Schermuly RT, Ghofrani HA, Grimminger F, Seeger W, Gudermann T, Weissmann N. Redox signaling and reactive oxygen species in hypoxic pulmonary vasoconstriction. Respir Physiol Neurobiol. 2010;174(3):282–91.

    Article  CAS  PubMed  Google Scholar 

  96. Olschewski A, Li Y, Tang B, Hanze J, Eul B, Bohle RM, Wilhelm J, Morty RE, Brau ME, Weir EK, et al. Impact of TASK-1 in human pulmonary artery smooth muscle cells. Circ Res. 2006;98(8):1072–80.

    Article  CAS  PubMed  Google Scholar 

  97. Weir EK, Olschewski A. Role of ion channels in acute and chronic responses of the pulmonary vasculature to hypoxia. Cardiovasc Res. 2006;71(4):630–41.

    Article  CAS  PubMed  Google Scholar 

  98. Tang B, Li Y, Nagaraj C, Morty RE, Gabor S, Stacher E, Voswinckel R, Weissmann N, Leithner K, Olschewski H, et al. Endothelin-1 inhibits background two-pore domain channel TASK-1 in primary human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol. 2009;41(4):476–83.

    Article  CAS  PubMed  Google Scholar 

  99. Herrera GM, Walker BR. Involvement of L-type calcium channels in hypoxic relaxation of vascular smooth muscle. J Vasc Res. 1998;35(4):265–73.

    Article  CAS  PubMed  Google Scholar 

  100. Shimoda LA, Polak J. Hypoxia. 4. Hypoxia and ion channel function. Am J Physiol Cell Physiol. 2011;300(5):C951–67.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  101. Kwapiszewska G, Wygrecka M, Marsh LM, Schmitt S, Trosser R, Wilhelm J, Helmus K, Eul B, Zakrzewicz A, Ghofrani HA, et al. Fhl-1, a new key protein in pulmonary hypertension. Circulation. 2008;118(11):1183–94.

    Article  CAS  PubMed  Google Scholar 

  102. Sims MW, Margolis DJ, Localio AR, Panettieri RA, Kawut SM, Christie JD. Impact of pulmonary artery pressure on exercise function in severe COPD. Chest. 2009;136(2):412–9.

    Article  PubMed Central  PubMed  Google Scholar 

  103. Thabut G, Dauriat G, Stern JB, Logeart D, Levy A, Marrash-Chahla R, Mal H. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest. 2005;127(5):1531–6.

    Article  PubMed  Google Scholar 

  104. Wright JL, Petty T, Thurlbeck WM. Analysis of the structure of the muscular pulmonary arteries in patients with pulmonary hypertension and COPD: National Institutes of Health nocturnal oxygen therapy trial. Lung. 1992;170(2):109–24.

    Article  CAS  PubMed  Google Scholar 

  105. Ferrer E, Peinado VI, Castaneda J, Prieto-Lloret J, Olea E, Gonzalez-Martin MC, Vega-Agapito MV, Diez M, Dominguez-Fandos D, Obeso A, et al. Effects of cigarette smoke and hypoxia on pulmonary circulation in the guinea pig. Eur Respir J. 2011;38(3):617–27.

    Article  CAS  PubMed  Google Scholar 

  106. Wright JL, Tai H, Churg A. Cigarette smoke induces persisting increases of vasoactive mediators in pulmonary arteries. Am J Respir Cell Mol Biol. 2004;31(5):501–9.

    Article  CAS  PubMed  Google Scholar 

  107. Wright JL, Tai H, Dai J, Churg A. Cigarette smoke induces rapid changes in gene expression in pulmonary arteries. Lab Invest. 2002;82(10):1391–8.

    Article  CAS  PubMed  Google Scholar 

  108. Yamato H, Sun JP, Churg A, Wright JL. Cigarette smoke-induced emphysema in guinea pigs is associated with diffusely decreased capillary density and capillary narrowing. Lab Invest. 1996;75(2):211–9.

    CAS  PubMed  Google Scholar 

  109. Lee SD, Lee DS, Chun YG, Shim TS, Lim CM, Koh Y, Kim WS, Kim DS, Kim WD. Cigarette smoke extract induces endothelin-1 via protein kinase C in pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol. 2001;281(2):L403–11.

    CAS  PubMed  Google Scholar 

  110. Nana-Sinkam SP, Lee JD, Sotto-Santiago S, Stearman RS, Keith RL, Choudhury Q, Cool C, Parr J, Moore MD, Bull TM, et al. Prostacyclin prevents pulmonary endothelial cell apoptosis induced by cigarette smoke. Am J Respir Crit Care Med. 2007;175(7):676–85.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  111. Peluffo G, Calcerrada P, Piacenza L, Pizzano N, Radi R. Superoxide-mediated inactivation of nitric oxide and peroxynitrite formation by tobacco smoke in vascular endothelium: studies in cultured cells and smokers. Am J Physiol Heart Circ Physiol. 2009;296(6):H1781–92.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  112. Edirisinghe I, Arunachalam G, Wong C, Yao H, Rahman A, Phipps RP, Jin ZG, Rahman I. Cigarette-smoke-induced oxidative/nitrosative stress impairs VEGF- and fluid-shear-stress-mediated signaling in endothelial cells. Antioxid Redox Signal. 2010;12(12):1355–69.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  113. Damico R, Simms T, Kim BS, Tekeste Z, Amankwan H, Damarla M, Hassoun PM. p53 mediates cigarette smoke-induced apoptosis of pulmonary endothelial cells: inhibitory effects of macrophage migration inhibitor factor. Am J Respir Cell Mol Biol. 2011;44(3):323–32.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  114. Milara J, Juan G, Ortiz JL, Guijarro R, Losada M, Serrano A, Morcillo EJ, Cortijo J. Cigarette smoke-induced pulmonary endothelial dysfunction is partially suppressed by sildenafil. Eur J Pharm Sci. 2010;39(5):363–72.

    Article  CAS  PubMed  Google Scholar 

  115. Dinh-Xuan AT, Higenbottam TW, Clelland CA, Pepke-Zaba J, Cremona G, Butt AY, Large SR, Wells FC, Wallwork J. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl J Med. 1991;324(22):1539–47.

    Article  CAS  PubMed  Google Scholar 

  116. Santos S, Peinado VI, Ramirez J, Morales-Blanhir J, Bastos R, Roca J, Rodriguez-Roisin R, Barbera JA. Enhanced expression of vascular endothelial growth factor in pulmonary arteries of smokers and patients with moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;167(9):1250–6.

    Article  PubMed  Google Scholar 

  117. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288(5789):373–6.

    Article  CAS  PubMed  Google Scholar 

  118. Stamler JS, Loh E, Roddy MA, Currie KE, Creager MA. Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation. 1994;89(5):2035–40.

    Article  CAS  PubMed  Google Scholar 

  119. Cremona G, Wood AM, Hall LW, Bower EA, Higenbottam T. Effect of inhibitors of nitric oxide release and action on vascular tone in isolated lungs of pig, sheep, dog and man. J Physiol. 1994;481 (Pt 1):185–95.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  120. Barbera JA, Roger N, Roca J, Rovira I, Higenbottam TW, Rodriguez-Roisin R. Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease. Lancet. 1996;347(8999):436–40.

    Article  CAS  PubMed  Google Scholar 

  121. Greenberg B, Kishiyama S. Endothelium-dependent and -independent responses to severe hypoxia in rat pulmonary artery. Am J Physiol. 1993;265(5 Pt 2):H1712–20.

    CAS  PubMed  Google Scholar 

  122. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328(24):1732–9.

    Article  CAS  PubMed  Google Scholar 

  123. Barbera JA, Peinado VI, Santos S, Ramirez J, Roca J, Rodriguez-Roisin R. Reduced expression of endothelial nitric oxide synthase in pulmonary arteries of smokers. Am J Respir Crit Care Med. 2001;164(4):709–13.

    Article  CAS  PubMed  Google Scholar 

  124. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995;333(4):214–21.

    Article  CAS  PubMed  Google Scholar 

  125. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59(7):574–80.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  126. Walter RE, Wilk JB, Larson MG, Vasan RS, Keaney JF Jr, Lipinska I, O’Connor GT, Benjamin EJ. Systemic inflammation and COPD: the Framingham Heart Study. Chest. 2008;133(1):19–25.

    Article  CAS  PubMed  Google Scholar 

  127. Saetta M, Baraldo S, Corbino L, Turato G, Braccioni F, Rea F, Cavallesco G, Tropeano G, Mapp CE, Maestrelli P, et al. CD8+ ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160(2):711–7.

    Article  CAS  PubMed  Google Scholar 

  128. Chaouat A, Savale L, Chouaid C, Tu L, Sztrymf B, Canuet M, Maitre B, Housset B, Brandt C, Le Corvoisier P, et al. Role for interleukin-6 in COPD-related pulmonary hypertension. Chest. 2009;136(3):678–87.

    Article  CAS  PubMed  Google Scholar 

  129. MacNee W. Oxidative stress and lung inflammation in airways disease. Eur J Pharmacol. 2001;429(1–3):195–207.

    Article  CAS  PubMed  Google Scholar 

  130. Pryor WA, Stone K. Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite. Ann N Y Acad Sci. 1993;686:12–27.

    Article  CAS  PubMed  Google Scholar 

  131. Dekhuijzen PN, Aben KK, Dekker I, Aarts LP, Wielders PL, van Herwaarden CL, Bast A. Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996;154(3 Pt 1):813–6.

    Article  CAS  PubMed  Google Scholar 

  132. Montuschi P, Collins JV, Ciabattoni G, Lazzeri N, Corradi M, Kharitonov SA, Barnes PJ. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med. 2000;162(3 Pt 1):1175–7.

    Article  CAS  PubMed  Google Scholar 

  133. Nowak D, Kasielski M, Antczak A, Pietras T, Bialasiewicz P. Increased content of thiobarbituric acid-reactive substances and hydrogen peroxide in the expired breath condensate of patients with stable chronic obstructive pulmonary disease: no significant effect of cigarette smoking. Respir Med. 1999;93(6):389–96.

    Article  CAS  PubMed  Google Scholar 

  134. Taggart C, Cervantes-Laurean D, Kim G, McElvaney NG, Wehr N, Moss J, Levine RL. Oxidation of either methionine 351 or methionine 358 in alpha 1-antitrypsin causes loss of anti-neutrophil elastase activity. J Biol Chem. 2000;275(35):27258–65.

    CAS  PubMed  Google Scholar 

  135. Cathcart MK. Regulation of superoxide anion production by NADPH oxidase in monocytes/macrophages: contributions to atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24(1):23–8.

    Article  CAS  PubMed  Google Scholar 

  136. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000;86(5):494–501.

    Article  CAS  PubMed  Google Scholar 

  137. Wink DA, Mitchell JB. Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radic Biol Med. 1998;25(4–5):434–56.

    Article  CAS  PubMed  Google Scholar 

  138. Szabo C, Ischiropoulos H, Radi R. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discov. 2007;6(8):662–80.

    Article  CAS  PubMed  Google Scholar 

  139. Fortuno A, San Jose G, Moreno MU, Diez J, Zalba G. Oxidative stress and vascular remodelling. Exp Physiol. 2005;90(4):457–62.

    Article  CAS  PubMed  Google Scholar 

  140. Griendling KK, Harrison DG. Dual role of reactive oxygen species in vascular growth. Circ Res. 1999;85(6):562–3.

    Article  CAS  PubMed  Google Scholar 

  141. Irani K. Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ Res. 2000;87(3):179–83.

    Article  CAS  PubMed  Google Scholar 

  142. Taniyama Y, Griendling KK. Reactive oxygen species in the vasculature: molecular and cellular mechanisms. Hypertension. 2003;42(6):1075–81.

    Article  CAS  PubMed  Google Scholar 

  143. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87(10):840–4.

    Article  CAS  PubMed  Google Scholar 

  144. Kojda G, Harrison D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res. 1999;43(3):562–71.

    Article  CAS  PubMed  Google Scholar 

  145. Li PF, Dietz R, von Harsdorf R. Differential effect of hydrogen peroxide and superoxide anion on apoptosis and proliferation of vascular smooth muscle cells. Circulation. 1997;96(10):3602–9.

    Article  CAS  PubMed  Google Scholar 

  146. Cai H. NAD(P)H oxidase-dependent self-propagation of hydrogen peroxide and vascular disease. Circ Res. 2005;96(8):818–22.

    Article  CAS  PubMed  Google Scholar 

  147. Touyz RM, Schiffrin EL. Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients: role of phospholipase D-dependent NAD(P)H oxidase-sensitive pathways. J Hypertens. 2001;19(7):1245–54.

    Article  CAS  PubMed  Google Scholar 

  148. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74(6):1141–8.

    Article  CAS  PubMed  Google Scholar 

  149. Zafari AM, Ushio-Fukai M, Akers M, Yin Q, Shah A, Harrison DG, Taylor WR, Griendling KK. Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy. Hypertension. 1998;32(3):488–95.

    Article  CAS  PubMed  Google Scholar 

  150. Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, Griendling KK. p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem. 1996;271(38):23317–21.

    Article  CAS  PubMed  Google Scholar 

  151. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90(3):251–62.

    CAS  PubMed  Google Scholar 

  152. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest. 1996;98(11):2572–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  153. Pu Q, Neves MF, Virdis A, Touyz RM, Schiffrin EL. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension. 2003;42(1):49–55.

    Article  CAS  PubMed  Google Scholar 

  154. Liu J, Yang F, Yang XP, Jankowski M, Pagano PJ. NAD(P)H oxidase mediates angiotensin II-induced vascular macrophage infiltration and medial hypertrophy. Arterioscler Thromb Vasc Biol. 2003;23(5):776–82.

    Article  CAS  PubMed  Google Scholar 

  155. Weissmann N, Lobo B, Pichl A, Parajuli N, Seimetz M, Puig-Pey R, Ferrer E, Peinado VI, Dominguez-Fandos D, Fysikopoulos A, et al. Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema. Am J Respir Crit Care Med. 2014;189(11):1359–73.

    Article  CAS  PubMed  Google Scholar 

  156. Dumitrascu R, Weissmann N, Ghofrani HA, Dony E, Beuerlein K, Schmidt H, Stasch JP, Gnoth MJ, Seeger W, Grimminger F, et al. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation. 2006;113(2):286–95.

    Article  CAS  PubMed  Google Scholar 

  157. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov. 2006;5(9):755–68.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  158. Li H, Forstermann U. Nitric oxide in the pathogenesis of vascular disease. J Pathol. 2000;190(3):244–54.

    Article  CAS  PubMed  Google Scholar 

  159. Arif E, Ahsan A, Vibhuti A, Rajput C, Deepak D, Athar M, Singh B, Pasha MA. Endothelial nitric oxide synthase gene variants contribute to oxidative stress in COPD. Biochem Biophys Res Commun. 2007;361(1):182–8.

    Article  CAS  PubMed  Google Scholar 

  160. Forstermann U. Oxidative stress in vascular disease: causes, defense mechanisms and potential therapies. Nat Clin Pract Cardiovasc Med. 2008;5(6):338–49.

    Article  PubMed  CAS  Google Scholar 

  161. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet. 2004;364(9435):709–21.

    Article  PubMed  Google Scholar 

  162. Kharitonov SA. NOS:molecular mechanisms, clinical aspects, therapeutic and monitoring approaches. Curr Drug Targets Inflamm Allergy. 2005;4(2):141–9.

    Article  CAS  PubMed  Google Scholar 

  163. Kharitonov SA, Barnes PJ. Nitric oxide, nitrotyrosine, and nitric oxide modulators in asthma and chronic obstructive pulmonary disease. Curr Allergy Asthma Rep. 2003;3(2):121–9.

    Article  PubMed  Google Scholar 

  164. Mueller CF, Laude K, McNally JS, Harrison DG. ATVB in focus: redox mechanisms in blood vessels. Arterioscler Thromb Vasc Biol. 2005;25(2):274–8.

    Article  CAS  PubMed  Google Scholar 

  165. Lassegue B, Clempus RE. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol. 2003;285(2):R277–97.

    Article  CAS  PubMed  Google Scholar 

  166. Cross AR, Segal AW. The NADPH oxidase of professional phagocytes–prototype of the NOX electron transport chain systems. Biochim Biophys Acta. 2004;1657(1):1–22.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  167. Selemidis S, Sobey CG, Wingler K, Schmidt HH, Drummond GR. NADPH oxidases in the vasculature: molecular features, roles in disease and pharmacological inhibition. Pharmacol Ther. 2008;120(3):254–91.

    Article  CAS  PubMed  Google Scholar 

  168. Geiszt M, Lekstrom K, Witta J, Leto TL. Proteins homologous to p47phox and p67phox support superoxide production by NAD(P)H oxidase 1 in colon epithelial cells. J Biol Chem. 2003;278(22):20006–12.

    Article  CAS  PubMed  Google Scholar 

  169. Ago T, Kuribayashi F, Hiroaki H, Takeya R, Ito T, Kohda D, Sumimoto H. Phosphorylation of p47phox directs phox homology domain from SH3 domain toward phosphoinositides, leading to phagocyte NADPH oxidase activation. Proc Natl Acad Sci U S A. 2003;100(8):4474–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  170. Brandes RP, Kreuzer J. Vascular NADPH oxidases: molecular mechanisms of activation. Cardiovasc Res. 2005;65(1):16–27.

    Article  CAS  PubMed  Google Scholar 

  171. De Keulenaer GW, Alexander RW, Ushio-Fukai M, Ishizaka N, Griendling KK. Tumour necrosis factor alpha activates a p22phox-based NADH oxidase in vascular smooth muscle. Biochem J. 1998;329(Pt 3):653–7.

    Article  PubMed Central  PubMed  Google Scholar 

  172. Zalba G, San Jose G, Beaumont FJ, Fortuno MA, Fortuno A, Diez J. Polymorphisms and promoter overactivity of the p22(phox) gene in vascular smooth muscle cells from spontaneously hypertensive rats. Circ Res. 2001;88(2):217–22.

    Article  CAS  PubMed  Google Scholar 

  173. Moreno MU, San Jose G, Orbe J, Paramo JA, Beloqui O, Diez J, Zalba G. Preliminary characterisation of the promoter of the human p22(phox) gene: identification of a new polymorphism associated with hypertension. FEBS Lett. 2003;542(1–3):27–31.

    Article  CAS  PubMed  Google Scholar 

  174. San Jose G, Moreno MU, Olivan S, Beloqui O, Fortuno A, Diez J, Zalba G. Functional effect of the p22phox—930 A/G polymorphism on p22phox expression and NADPH oxidase activity in hypertension. Hypertension. 2004;44(2):163–9.

    Article  CAS  PubMed  Google Scholar 

  175. Fortuno A, Olivan S, Beloqui O, San Jose G, Moreno MU, Diez J, Zalba G. Association of increased phagocytic NADPH oxidase-dependent superoxide production with diminished nitric oxide generation in essential hypertension. J Hypertens. 2004;22(11):2169–75.

    Article  CAS  PubMed  Google Scholar 

  176. Wick MJ, Buesing EJ, Wehling CA, Loomis ZL, Cool CD, Zamora MR, Miller YE, Colgan SP, Hersh LB, Voelkel NF, et al. Decreased neprilysin and pulmonary vascular remodeling in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;183(3):330–40.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  177. Sunday ME, Hua J, Torday JS, Reyes B, Shipp MA. CD10/neutral endopeptidase 24.11 in developing human fetal lung. Patterns of expression and modulation of peptide-mediated proliferation. J Clin Invest. 1992;90(6):2517–25.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  178. Dusser DJ, Djokic TD, Borson DB, Nadel JA. Cigarette smoke induces bronchoconstrictor hyperresponsiveness to substance P and inactivates airway neutral endopeptidase in the guinea pig. Possible role of free radicals. J Clin Invest. 1989;84(3):900–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  179. Carpenter TC, Stenmark KR. Hypoxia decreases lung neprilysin expression and increases pulmonary vascular leak. Am J Physiol Lung Cell Mol Physiol. 2001;281(4):L941–8.

    CAS  PubMed  Google Scholar 

  180. Dempsey EC, Wick MJ, Karoor V, Barr EJ, Tallman DW, Wehling CA, Walchak SJ, Laudi S, Le M, Oka M, et al. Neprilysin null mice develop exaggerated pulmonary vascular remodeling in response to chronic hypoxia. Am J Pathol. 2009;174(3):782–96.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  181. Shinall H, Song ES, Hersh LB. Susceptibility of amyloid beta peptide degrading enzymes to oxidative damage: a potential Alzheimer’s disease spiral. Biochemistry. 2005;44(46):15345–50.

    Article  CAS  PubMed  Google Scholar 

  182. Papandreou CN, Nanus DM. Is methylation the key to CD10 loss? J Pediatr Hematol Oncol. 2010;32(1):2–3.

    Article  PubMed  Google Scholar 

  183. Sumitomo M, Shen R, Nanus DM. Involvement of neutral endopeptidase in neoplastic progression. Biochim Biophys Acta. 2005;1751(1):52–9.

    Article  CAS  PubMed  Google Scholar 

  184. Karoor V, Oka M, Walchak SJ, Hersh LB, Miller YE, Dempsey EC. Neprilysin regulates pulmonary artery smooth muscle cell phenotype through a platelet-derived growth factor receptor-dependent mechanism. Hypertension. 2013;61(4):921–30.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  185. Lee SH, Channick RN. Endothelin antagonism in pulmonary arterial hypertension. Semin Respir Crit Care Med. 2005;26(4):402–8.

    Article  PubMed  Google Scholar 

  186. Jensen RT, Battey JF, Spindel ER, Benya RV. International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol Rev. 2008;60(1):1–42.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  187. Nemenoff RA, Simpson PA, Furgeson SB, Kaplan-Albuquerque N, Crossno J, Garl PJ, Cooper J, Weiser-Evans MC. Targeted deletion of PTEN in smooth muscle cells results in vascular remodeling and recruitment of progenitor cells through induction of stromal cell-derived factor-1alpha. Circ Res. 2008;102(9):1036–45.

    Article  CAS  PubMed  Google Scholar 

  188. Klinger JR, Petit RD, Warburton RR, Wrenn DS, Arnal F, Hill NS. Neutral endopeptidase inhibition attenuates development of hypoxic pulmonary hypertension in rats. J Appl Physiol. 1993;75(4):1615–23.

    CAS  PubMed  Google Scholar 

  189. Thompson JS, Morice AH. Neutral endopeptidase inhibitors and the pulmonary circulation. Gen Pharmacol. 1996;27(4):581–5.

    Article  CAS  PubMed  Google Scholar 

  190. Casserly B, Klinger JR. Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent. Drug Des Devel Ther. 2009;3:269–87.

    PubMed Central  CAS  PubMed  Google Scholar 

  191. Feil R, Lohmann SM, de Jonge H, Walter U, Hofmann F. Cyclic GMP-dependent protein kinases and the cardiovascular system: insights from genetically modified mice. Circ Res. 2003;93(10):907–16.

    Article  CAS  PubMed  Google Scholar 

  192. Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, Chepenik KP, Waldman SA. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev. 2000;52(3):375–414.

    CAS  PubMed  Google Scholar 

  193. Silberbach M, Roberts CT Jr. Natriuretic peptide signalling: molecular and cellular pathways to growth regulation. Cell Signal. 2001;13(4):221–31.

    Article  CAS  PubMed  Google Scholar 

  194. Hamet P, Tremblay J, Pang SC, Skuherska R, Schiffrin EL, Garcia R, Cantin M, Genest J, Palmour R, Ervin FR, et al. Cyclic GMP as mediator and biological marker of atrial natriuretic factor. J Hypertens Suppl. 1986;4(2):49–56.

    Google Scholar 

  195. Corti R, Burnett JC Jr, Rouleau JL, Ruschitzka F, Luscher TF. Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation. 2001;104(15):1856–62.

    Article  CAS  PubMed  Google Scholar 

  196. Daull P, Jeng AY, Battistini B. Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases. J Cardiovasc Pharmacol. 2007;50(3):247–56.

    Article  CAS  PubMed  Google Scholar 

  197. Maki T, Nasa Y, Yamaguchi F, Yoshida H, Mori M, Takada T, Horikawa E, Okano K, Takeo S. Long-term treatment with neutral endopeptidase inhibitor improves cardiac function and reduces natriuretic peptides in rats with chronic heart failure. Cardiovasc Res. 2001;51(3):608–17.

    Article  CAS  PubMed  Google Scholar 

  198. Xu J, Carretero OA, Liu YH, Yang F, Shesely EG, Oja-Tebbe N, Yang XP. Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure. J Card Fail. 2004;10(1):83–9.

    CAS  PubMed  Google Scholar 

  199. Sumitomo M, Iwase A, Zheng R, Navarro D, Kaminetzky D, Shen R, Georgescu MM, Nanus DM. Synergy in tumor suppression by direct interaction of neutral endopeptidase with PTEN. Cancer Cell. 2004;5(1):67–78.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Excellence Cluster Cardio-Pulmonary System (ECCPS), Aulweg 130, ECCPS, 35392, Giessen, Germany

    Dr. rer. nat. Michael Seimetz & Dr. rer. nat. Norbert Weissmann

  2. Universities of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany

    Dr. rer. nat. Michael Seimetz & Dr. rer. nat. Norbert Weissmann

  3. German Center for Lung Research (DZL), Giessen, Germany

    Dr. rer. nat. Michael Seimetz & Dr. rer. nat. Norbert Weissmann

  4. Justus-Liebig-University, Giessen, Germany

    Dr. rer. nat. Michael Seimetz & Dr. rer. nat. Norbert Weissmann

Authors
  1. Dr. rer. nat. Michael Seimetz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. rer. nat. Norbert Weissmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Seimetz .

Editor information

Editors and Affiliations

  1. Microscopic Anatomy and Neurobiology Building 708, 2.Floor, R2.006, Johannes Gutenberg University School of Medicine, Mainz, Germany

    Mirko HH Schmidt

  2. Institute of Neurology Building 89, 4.Floor, R402, Goethe University Frankfurt School of Medicine, Frankfurt, Germany

    Stefan Liebner

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Seimetz, M., Weissmann, N. (2015). The Pulmonary Vasculature in Chronic Obstructive Lung Disease. In: Schmidt, M., Liebner, S. (eds) Endothelial Signaling in Development and Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2907-8_15

Download citation

Publish with us

Policies and ethics

Search

Navigation